AtriCure's improved tissue ablator:
This article was originally published in Clinica
Executive Summary
The US FDA has given AtriCure 510(k) marketing clearance to use its Isolator Synergy bipolar ablation system on soft tissue. The device is a next generation version of the firm's FDA-cleared Isolator bipolar ablation system; neither product has yet been cleared for cardiac use or for treating atrial fibrillation. It incorporates two pulsing pairs of electrodes in the jaws of the clamp to create a uniform, full-thickness ablation lesion shaped like a column, which the West Chester, Ohio firm believes will result in more durable ablation lines in thicker and more diseased tissues. The company anticipates launching a minimally-invasive version of the device during the third quarter of 2007.
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.